Why is Medicamen Biotec falling/rising?

As of 22-Jul, Medicamen Biotech Ltd is experiencing a decline in its stock price, currently at 398.80, which reflects a decrease of 2.3 or 0.57%. The stock has been underperforming recently, having fallen for three consecutive days with a total decline of 2.97%. Although it outperformed its sector by 0.34% today, the stock's performance over the past month shows a decrease of 1.29%, and it has significantly underperformed the benchmark indices over the past year, with a return of -12.30%. The company also faces challenges such as a low return on capital employed (ROCE) of 2.8 and declining net sales, which have contributed to a negative outlook.
In the broader market context, the Sensex has shown a slight decline of 0.47% over the past week, while Medicamen Biotech's stock has increased by 3.41% in the same period, indicating a short-term outperformance. However, the long-term picture is concerning, as the stock has underperformed the benchmark consistently over the last three years, with a staggering decline of 43.63% compared to the Sensex's 46.57% gain. The company's poor long-term growth, evidenced by a significant drop in operating profit and cash reserves, further exacerbates investor concerns, leading to a lack of participation in trading as reflected by a 48.62% drop in delivery volume.